Novartis AG $NVS Shares Bought by Sivia Capital Partners LLC

Sivia Capital Partners LLC grew its stake in shares of Novartis AG (NYSE:NVS) by 83.2% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 13,595 shares of the company’s stock after purchasing an additional 6,175 shares during the quarter. Sivia Capital Partners LLC’s holdings in Novartis were worth $1,874,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently modified their holdings of NVS. Arlington Trust Co LLC acquired a new position in shares of Novartis during the fourth quarter worth about $25,000. Measured Wealth Private Client Group LLC acquired a new position in shares of Novartis during the third quarter worth about $33,000. South Plains Financial Inc. lifted its stake in shares of Novartis by 39.0% during the third quarter. South Plains Financial Inc. now owns 271 shares of the company’s stock worth $35,000 after purchasing an additional 76 shares in the last quarter. Aventura Private Wealth LLC acquired a new position in shares of Novartis during the fourth quarter worth about $45,000. Finally, Cornerstone Planning Group LLC lifted its stake in shares of Novartis by 15,950.0% during the fourth quarter. Cornerstone Planning Group LLC now owns 321 shares of the company’s stock worth $47,000 after purchasing an additional 319 shares in the last quarter. Institutional investors and hedge funds own 13.12% of the company’s stock.

Novartis Stock Up 0.2%

Shares of Novartis stock opened at $143.70 on Thursday. The company has a quick ratio of 0.65, a current ratio of 0.85 and a debt-to-equity ratio of 0.96. The firm has a market cap of $274.20 billion, a P/E ratio of 20.59, a P/E/G ratio of 2.52 and a beta of 0.46. Novartis AG has a fifty-two week low of $112.34 and a fifty-two week high of $170.46. The business has a 50-day moving average price of $149.60 and a 200 day moving average price of $147.14.

Novartis (NYSE:NVS) last announced its quarterly earnings data on Monday, April 27th. The company reported $1.99 earnings per share for the quarter, missing the consensus estimate of $2.11 by ($0.12). The firm had revenue of $13.52 billion during the quarter, compared to the consensus estimate of $13.44 billion. Novartis had a net margin of 24.87% and a return on equity of 38.82%. The firm’s quarterly revenue was down .9% compared to the same quarter last year. During the same period in the prior year, the firm earned $2.28 earnings per share. On average, sell-side analysts forecast that Novartis AG will post 8.84 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research analysts have commented on the company. TD Cowen restated a “hold” rating on shares of Novartis in a research note on Tuesday, February 17th. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating on shares of Novartis in a research report on Thursday, February 12th. Weiss Ratings lowered Novartis from a “buy (a-)” rating to a “buy (b)” rating in a research report on Wednesday, April 29th. Wall Street Zen lowered Novartis from a “buy” rating to a “hold” rating in a research report on Saturday, February 7th. Finally, Morgan Stanley lifted their target price on Novartis from $143.00 to $170.00 and gave the stock an “overweight” rating in a research report on Thursday, March 26th. Seven investment analysts have rated the stock with a Buy rating, seven have issued a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Hold” and an average target price of $141.20.

Novartis Profile

Novartis is a Swiss multinational pharmaceutical company headquartered in Basel that researches, develops, manufactures and commercializes prescription medicines and related health-care products. Formed through the 1996 merger of Ciba-Geigy and Sandoz, Novartis operates globally and focuses on bringing therapeutics from discovery through clinical development to commercial markets worldwide.

The company’s activities center on innovative pharmaceuticals across several therapeutic areas, including oncology, immunology, cardiovascular and metabolic diseases, neuroscience and ophthalmology, alongside capabilities in advanced therapies such as biologics, cell and gene therapies.